BIOMAT Database Logo BIOMAT Database Logo

[The combination of amoxicillin-clavulanic acid and ofloxacin in the treatment of multidrug-resistant Mycobacterium tuberculosis]. 1997

T Iwanaga, and K Yokota, and R Kishikawa, and T Ikeda, and H Tsurutani, and T Hirose, and S Nishima
Department of Pulmonary Medicine, National Minami-Fukuoka Chest Hospital, Fukuoka, Japan.

A 67-year-old [correction of 53] man with multidrug resistant tuberculosis (MDR-TB) had been persistently positive for acid-fast bacilli (AFB) both on sputum smear and also on culture with the Ogawa egg medium for 30 years since 1951. The case had been treated previously with isoniazid, rifampin, streptomycin, ethambutol, kanamycin, ethionamide, paraaminosalicylate and cycloserine; however, M. tuberculosis strains isolated from this patient acquired a high resistance to all of these agents. Then, a new regimen of chemotherapy, INH combined with ofloxacin (OFLX) and amoxicillin-clavulanic acid (AMPC/ CVA), was applied to the case. He was successfully treated with this regimen, and a marked decrease in the amount of AFB on smear as well as on culture was observed during the course of chemotherapy. No adverse effects were seen meanwhile. These data suggest that it is worth while to try a regimen containing AMPC/CVA and OFLX in the treatment of MDR-TB.

UI MeSH Term Description Entries
D007538 Isoniazid Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. Isonicotinic Acid Hydrazide,Ftivazide,Isonex,Isonicotinic Acid Vanillylidenehydrazide,Phthivazid,Phthivazide,Tubazide,Acid Vanillylidenehydrazide, Isonicotinic,Hydrazide, Isonicotinic Acid,Vanillylidenehydrazide, Isonicotinic Acid
D008297 Male Males
D002969 Clavulanic Acids Acids, salts, and derivatives of clavulanic acid (C8H9O5N). They consist of those beta-lactam compounds that differ from penicillin in having the sulfur of the thiazolidine ring replaced by an oxygen. They have limited antibacterial action, but block bacterial beta-lactamase irreversibly, so that similar antibiotics are not broken down by the bacterial enzymes and therefore can exert their antibacterial effects. Acids, Clavulanic
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000658 Amoxicillin A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration. Hydroxyampicillin,Actimoxi,Amoxicillin Anhydrous,Amoxicillin Monopotassium Salt,Amoxicillin Monosodium Salt,Amoxicillin Sodium,Amoxicillin Trihydrate,Amoxicillin, (R*)-Isomer,Amoxicilline,Amoxil,Amoxycillin,BRL-2333,Clamoxyl,Clamoxyl G.A.,Clamoxyl Parenteral,Penamox,Polymox,Trimox,Wymox,BRL 2333,BRL2333
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D014397 Tuberculosis, Pulmonary MYCOBACTERIUM infections of the lung. Pulmonary Consumption,Pulmonary Phthisis,Pulmonary Tuberculoses,Pulmonary Tuberculosis,Tuberculoses, Pulmonary,Consumption, Pulmonary,Consumptions, Pulmonary,Phthises, Pulmonary,Phthisis, Pulmonary,Pulmonary Consumptions,Pulmonary Phthises

Related Publications

T Iwanaga, and K Yokota, and R Kishikawa, and T Ikeda, and H Tsurutani, and T Hirose, and S Nishima
Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis.
April 1991, Chest,
T Iwanaga, and K Yokota, and R Kishikawa, and T Ikeda, and H Tsurutani, and T Hirose, and S Nishima
[Comparative study of ofloxacin+amoxicillin-clavulanic acid versus doxycycline+amoxicillin-clavulanic acid combination in the treatment of pelvic Chlamydia trachomatis infections].
January 1995, Journal de gynecologie, obstetrique et biologie de la reproduction,
T Iwanaga, and K Yokota, and R Kishikawa, and T Ikeda, and H Tsurutani, and T Hirose, and S Nishima
In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis.
September 1983, Antimicrobial agents and chemotherapy,
T Iwanaga, and K Yokota, and R Kishikawa, and T Ikeda, and H Tsurutani, and T Hirose, and S Nishima
Susceptibility of multidrug-resistant strains of Mycobacterium tuberculosis to amoxycillin in combination with clavulanic acid and ethambutol.
December 1998, The Journal of antimicrobial chemotherapy,
T Iwanaga, and K Yokota, and R Kishikawa, and T Ikeda, and H Tsurutani, and T Hirose, and S Nishima
Use of amikacin and amoxicillin-clavulanic acid against Mycobacterium tuberculosis.
July 1993, Chest,
T Iwanaga, and K Yokota, and R Kishikawa, and T Ikeda, and H Tsurutani, and T Hirose, and S Nishima
Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.
January 2015, Antimicrobial agents and chemotherapy,
T Iwanaga, and K Yokota, and R Kishikawa, and T Ikeda, and H Tsurutani, and T Hirose, and S Nishima
Ofloxacin in multidrug resistant tuberculosis.
March 2003, Journal of the Indian Medical Association,
T Iwanaga, and K Yokota, and R Kishikawa, and T Ikeda, and H Tsurutani, and T Hirose, and S Nishima
A combination of amoxicillin and clavulanic acid in the treatment of respiratory tract infections caused by amoxicillin-resistant haemophilus influenzae.
January 1981, Infection,
T Iwanaga, and K Yokota, and R Kishikawa, and T Ikeda, and H Tsurutani, and T Hirose, and S Nishima
Treatment outcomes and moxifloxacin susceptibility in ofloxacin-resistant multidrug-resistant tuberculosis.
January 2014, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease,
T Iwanaga, and K Yokota, and R Kishikawa, and T Ikeda, and H Tsurutani, and T Hirose, and S Nishima
[Kinetics of ofloxacin-amoxicillin and ofloxacin-clavulanic acid combinations against pathogenic bacteria of the respiratory tract].
May 1988, Pathologie-biologie,
Copied contents to your clipboard!